Cover ImageSALE
市場調查報告書

子宮頸癌診斷檢驗的全球市場:2016∼2020年

Global Cervical Cancer Diagnostic Testing Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 321448
出版日期 內容資訊 英文 111 Pages
訂單完成後即時交付
價格
Back to Top
子宮頸癌診斷檢驗的全球市場:2016∼2020年 Global Cervical Cancer Diagnostic Testing Market 2016-2020
出版日期: 2016年12月08日 內容資訊: 英文 111 Pages
簡介

全球子宮頸癌診斷檢驗市場,預計2016∼2020年以6.90%的年複合成長率擴大。

本報告提供全球子宮頸癌診斷檢驗市場現狀與今後的預測,市場規模,各市場區隔的銷售趨勢,各地區趨勢,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

  • 市場概要
  • 主要產品

第3章 市場調查方法

  • 調查方法
  • 經濟指標

第4章 簡介

第5章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第6章 各檢查市場區隔

  • 子宮頸部細胞診斷(子宮頸抹片)
  • HPV檢驗
  • 全球子宮頸部細胞診斷市場
  • 全球HPV檢驗市場

第7章 各技術市場區隔

  • ELISA
  • FISH
  • NASBA
  • PCR
  • 多種顏色染色法/陰道鏡檢查

第8章 各手法市場區隔

  • 細胞病理學法
  • 分子法

第9章 各終端用戶市場區隔

  • 醫院
  • 臨床檢驗研究所
  • 居家醫療
  • 其他

第10章 各地區市場區隔

  • 南北美洲
  • EMEA
  • 亞太地區

第11章 購買標準

第12章 市場成長的促進要素

第13章 促進要素的影響

第14章 市場課題

第15章 推動市場的要素與課題的影響

第16章 市場趨勢

第17章 供應商環境

  • 競爭模式
  • 主要供應商的地理存在感
  • 主要消息

第18章 主要供應商分析

  • Abbott Molecular
  • Becton, Dickinson & Company (BD)
  • Hologic
  • QIAGEN
  • Quest Diagnostics
  • Roche Molecular Diagnostics
  • 其他值得注意的供應商

第19章 附錄

  • 簡稱說明

第20章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR11062

About Cervical Cancer Diagnostic Testing

The global cervical cancer diagnostic testing market is growing steadily, primarily due to the availability and awareness of the programs in the developed countries. This test enables women aged 21 years and above to get screened, making most of the pre-cancerous lesions identifiable at stages when they can be treated easily. In the US, National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides low-cost even free cervical cancer screening for uninsured and low-income women. As per the Affordable Care Act, all health insurance plans initiated after September 23, 2010, should provide recommended cervical cancer screening tests to end-users. In developing countries, with the widespread awareness programs by public organizations like the WHO along with government initiatives, visual inspection with acetic acid (VIA) and Lugol's iodine (VILI) are being performed to screen women. This initiative is expected to raise the market demand for cervical cancer screening and diagnostic tests.

Technavio's analysts forecast the global cervical cancer diagnostic testing market to grow at a CAGR of 6.90% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global cervical cancer diagnostic testing market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of cervical cancer testing products used to perform cervical cancer screening.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Cervical Cancer Diagnostic Testing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Abbott Molecular
  • Becton
  • Dickinson & Company
  • Hologic
  • Qiagen
  • Quest Diagnostics
  • Roche Molecular Diagnostics

Other Prominent Vendors

  • Arbor Vita
  • Autogenomics
  • bioMerieux
  • BioVantra
  • Cancer Genetics
  • Cepheid
  • Cervia Diagnostics
  • Cytoimmun
  • DAAN Gene
  • Delphi Bioscience
  • DiaCarta
  • Fujirebio
  • Genera Biosystems
  • Greiner Bio-One
  • Guided Therapeutics
  • GynaeHealth
  • IncellDx
  • Micromedic Technologies
  • Norchip
  • OncoHealth
  • OralDNA Labs
  • Seegene
  • Solopap International
  • Trovagene

Market driver

  • Increasing global activities by public organizations.
  • For a full, detailed list, view our report

Market challenge

  • Rising awareness toward cervical cancer over-screening.
  • For a full, detailed list, view our report

Market trend

  • Development of new diagnostic platforms.
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

Market overview

  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

Key market highlights

  • Cervical cancer: An overview

PART 05: Market landscape

Market overview

  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by test type

  • Pap smear test
  • HPV testing
  • Global cervical cancer Pap smear test market
  • Global cervical cancer HPV testing market

PART 07: Market segmentation by technology

  • ELISA
  • FISH
  • NASBA
  • PCR
  • Multichromatic staining and microscopy

PART 08: Market segmentation by method

  • Cytopathological method
  • Molecular method

PART 09: Market segmentation by end-user

  • Hospitals
  • Clinical diagnostic laboratories
  • Homecare
  • Others

PART 10: Geographical segmentation

  • Cervical cancer diagnostic testing market in Americas
  • Cervical cancer diagnostic testing market in EMEA
  • Cervical cancer diagnostic testing market in APAC

PART 11: Buying criteria

PART 12: Market drivers

  • Rising prevalence of cervical cancer risk factors
  • Growing adoption of HPV testing
  • Reimbursement policies
  • Increasing global activities by public organizations

PART 13: Impact of drivers

PART 14: Market challenges

  • Rising awareness toward cervical cancer over-screening
  • Less public awareness and presence of social barriers
  • Limited number of health clinics in developing countries
  • Availability of visual inspection methods

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Development of new diagnostic platforms
  • Expansion into emerging markets
  • Emergence of novel biomarkers
  • Rise in use of HPV home-testing kits

PART 17: Vendor landscape

  • Competitive scenario
  • Geographical presence of key vendors
  • Key news

PART 18: Key vendor analysis

  • Abbott Molecular
  • Becton, Dickinson & Company (BD)
  • Hologic
  • QIAGEN
  • Quest Diagnostics
  • Roche Molecular Diagnostics
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global cervical cancer diagnostic testing market: Analysis
  • Exhibit 03: Global incidence of cervical cancer 2012-2020 (thousands)
  • Exhibit 04: Incidences of cervical cancer in developing and developed countries 2012-2020 (in thousands)
  • Exhibit 05: Market overview: Global cervical cancer diagnostic testing market
  • Exhibit 06: Global cervical cancer diagnostic testing market ($ billions)
  • Exhibit 07: Global cervical cancer diagnostic testing market analysis: Developed and emerging markets
  • Exhibit 08: Opportunity analysis: Global cervical cancer diagnostic testing market
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Global cervical cancer diagnostic testing market by test type 2015
  • Exhibit 11: Global cervical cancer diagnostic testing market by test type 2020
  • Exhibit 12: Major cervical cancer diagnostic products
  • Exhibit 13: Global cervical cancer Pap smear test market 2015-2020 ($ billions)
  • Exhibit 14: Global cervical cancer HPV testing market 2015-2020 ($ millions)
  • Exhibit 15: Segmentation of global cervical cancer HPV testing market by product type
  • Exhibit 16: Global cervical cancer diagnostic testing market segmentation by test type 2015-2020 ($ millions)
  • Exhibit 17: Global cervical cancer diagnostic testing market segmentation by test type 2015-2020 (%)
  • Exhibit 18: List of some studies for cervical cancer screening using ELISA technique
  • Exhibit 19: List of some studies for cervical cancer screening using FISH technique
  • Exhibit 20: List of some studies for cervical cancer screening using NASBA technique
  • Exhibit 21: List of some studies for cervical cancer screening using PCR technique
  • Exhibit 22: List of some studies for cervical cancer screening using Multichromatic staining and microscopy technique
  • Exhibit 23: Some cervical cancer diagnostic test products by technology
  • Exhibit 24: Global cervical cancer diagnostic testing market by method 2015
  • Exhibit 25: Global cervical cancer diagnostic testing market by method 2020
  • Exhibit 26: Global cervical cancer diagnostic testing market segmentation by end users 2015
  • Exhibit 27: Global cervical cancer diagnostic testing market segmentation by geography 2015
  • Exhibit 28: Global cervical cancer diagnostic testing market segmentation by geography 2020
  • Exhibit 29: Region-wise market impact: Global cervical cancer diagnostics market
  • Exhibit 30: Country-wise revenue and growth analysis
  • Exhibit 31: Global cervical cancer diagnostic testing market: Geography lifecycle analysis 2015
  • Exhibit 32: Market overview: Americas
  • Exhibit 33: Cervical cancer diagnostic testing market in Americas 2016-2020 ($ millions)
  • Exhibit 34: Market overview: EMEA
  • Exhibit 35: Cervical cancer diagnostic testing in EMEA 2016-2020 ($ millions)
  • Exhibit 36: Market overview: APAC
  • Exhibit 37: Cervical cancer diagnostic testing market in APAC 2016-2020 ($ millions)
  • Exhibit 38: Comparison of cervical cancer incidences in developed and developing countries 2012-2020 (in thousands)
  • Exhibit 39: Global cervical cancer diagnostic testing market segmentation by geography 2015-2020 (%)
  • Exhibit 40: Global cervical cancer diagnostic testing market segmentation by geography 2015-2020 ($ millions)
  • Exhibit 41: Geographical overview: Global cervical cancer diagnostic testing market
  • Exhibit 42: Key buying criteria for cervical cancer diagnostic testing
  • Exhibit 43: Buying criteria for cervical cancer diagnostic testing
  • Exhibit 44: Country-wise percentage of women who smoke on a daily-basis
  • Exhibit 45: Country-wise statistics of cervical cancer cases per 100,000 women per year
  • Exhibit 46: Reimbursement policies in different countries
  • Exhibit 47: Activities of CDC in collaboration with other public organizations for cervical cancer screening
  • Exhibit 48: Impact of drivers
  • Exhibit 49: Cervical cancer cases comparison in North-Americas and Africa
  • Exhibit 50: Impact of drivers and challenges
  • Exhibit 51: Expansion of global market leaders in developing countries/regions
  • Exhibit 52: List of cervical cancer diagnostic studies for novel biomarker detection
  • Exhibit 53: Trends and their impact
  • Exhibit 54: Competitive structure analysis of global cervical cancer testing market 2015
  • Exhibit 55: Market penetration of various cervical cancer diagnostic testing manufacturers globally (2015)
  • Exhibit 56: Competitive landscape analysis of global cervical cancer diagnostic testing market 2015
  • Exhibit 57: Strategic success factors of companies in global cervical cancer diagnostic testing market 2015
  • Exhibit 58: Leading vendors ranking 2015
  • Exhibit 59: Share of vendors in global cervical cancer diagnostic testing market 2015
  • Exhibit 60: Regional analysis of key vendors
  • Exhibit 61: Key highlights of Abbott Molecular
  • Exhibit 62: Abbott Molecular strength assessment
  • Exhibit 63: Abbott Molecular strategy assessment
  • Exhibit 64: Abbott Molecular opportunity assessment
  • Exhibit 65: Key highlights of BD
  • Exhibit 66: BD strength assessment
  • Exhibit 67: BD strategy assessment
  • Exhibit 68: BD opportunity assessment
  • Exhibit 69: Key highlights of Hologic
  • Exhibit 70: Hologic strength assessment
  • Exhibit 71: Hologic strategy assessment
  • Exhibit 72: Hologic opportunity assessment
  • Exhibit 73: Key highlights of QIAGEN
  • Exhibit 74: QIAGEN strength assessment
  • Exhibit 75: QIAGEN strategy assessment
  • Exhibit 76: QIAGEN opportunity assessment
  • Exhibit 77: Key highlights of Quest Diagnostics
  • Exhibit 78: Quest Diagnostics strength assessment
  • Exhibit 79: Quest Diagnostics strategy assessment
  • Exhibit 80: Quest Diagnostics opportunity assessment
  • Exhibit 81: Key highlights of Roche Molecular Diagnostics
  • Exhibit 82: Roche Molecular Diagnostics strength assessment
  • Exhibit 83: Roche Molecular Diagnostics strategy assessment
  • Exhibit 84: Roche Molecular Diagnostics opportunity assessment
Back to Top